TIL therapy uses cells derived from which source?

TIL therapy uses cells derived from which source?

• A. The patient's own tumor tissue
• B. Donor blood
• C. Animal model
• D. Synthetic peptides

Answer: (A)

Tumor-infiltrating lymphocyte therapy uses autologous immune cells collected directly from the patient’s own tumor tissue. These T cells have been in the tumor environment and are enriched for tumor-reactive cells. They’re expanded outside the body, often with interleukin-2, and then infused back into the patient after a conditioning regimen to help them persist and attack the cancer. This patient-derived tumor source is what gives TIL therapy its tumor specificity while avoiding rejection risks associated with donor cells. The other sources don’t fit because donor blood would be allogeneic, an animal model isn’t used to treat humans, and synthetic peptides are not cells.

Tumor-infiltrating lymphocyte therapy uses autologous immune cells collected directly from the patient’s own tumor tissue. These T cells have been in the tumor environment and are enriched for tumor-reactive cells. They’re expanded outside the body, often with interleukin-2, and then infused back into the patient after a conditioning regimen to help them persist and attack the cancer. This patient-derived tumor source is what gives TIL therapy its tumor specificity while avoiding rejection risks associated with donor cells. The other sources don’t fit because donor blood would be allogeneic, an animal model isn’t used to treat humans, and synthetic peptides are not cells.